• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity . Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

tetano

Editor, Senior Moderator
Immunity


. 2024 Apr 18:S1074-7613(24)00143-2.
doi: 10.1016/j.immuni.2024.03.022. Online ahead of print. Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

Rashmi Ray[SUP] 1 [/SUP], Faez Amokrane Nait Mohamed[SUP] 2 [/SUP], Daniel P Maurer[SUP] 1 [/SUP], Jiachen Huang[SUP] 3 [/SUP], Berk A Alpay[SUP] 4 [/SUP], Larance Ronsard[SUP] 1 [/SUP], Zhenfei Xie[SUP] 1 [/SUP], Julianna Han[SUP] 3 [/SUP], Monica Fernandez-Quintero[SUP] 5 [/SUP], Quynh Anh Phan[SUP] 1 [/SUP], Rebecca L Ursin[SUP] 1 [/SUP], Mya Vu[SUP] 1 [/SUP], Kathrin H Kirsch[SUP] 1 [/SUP], Thavaleak Prum[SUP] 1 [/SUP], Victoria C Rosado[SUP] 1 [/SUP], Thalia Bracamonte-Moreno[SUP] 1 [/SUP], Vintus Okonkwo[SUP] 1 [/SUP], Julia Bals[SUP] 1 [/SUP], Caitlin McCarthy[SUP] 1 [/SUP], Usha Nair[SUP] 1 [/SUP], Masaru Kanekiyo[SUP] 6 [/SUP], Andrew B Ward[SUP] 3 [/SUP], Aaron G Schmidt[SUP] 7 [/SUP], Facundo D Batista[SUP] 8 [/SUP], Daniel Lingwood[SUP] 9 [/SUP]



Affiliations
Abstract

Broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin (HA) stem of influenza A viruses (IAVs) tend to be effective against either group 1 or group 2 viral diversity. In rarer cases, intergroup protective bnAbs can be generated by human antibody paratopes that accommodate the conserved glycan differences between the group 1 and group 2 stems. We applied germline-engaging nanoparticle immunogens to elicit a class of cross-group bnAbs from physiological precursor frequency within a humanized mouse model. Cross-group protection depended on the presence of the human bnAb precursors within the B cell repertoire, and the vaccine-expanded antibodies enriched for an N55T substitution in the CDRH2 loop, a hallmark of the bnAb class. Structurally, this single mutation introduced a flexible fulcrum to accommodate glycosylation differences and could alone enable cross-group protection. Thus, broad IAV immunity can be expanded from the germline repertoire via minimal antigenic input and an exceptionally simple antibody development pathway.

Keywords: human antibody repertoire; immunogen; influenza virus; somatic hypermutation; universal; vaccine.

 
Back
Top Bottom